Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

89Bio Inc (NQ: ETNB )

9.140 +0.240 (+2.70%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 89Bio Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
From 89bio, Inc.
Via GlobeNewswire
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
New post-hoc analyses reinforce pegozafermin’s potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints 
From 89bio, Inc.
Via GlobeNewswire
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
ETNB Stock Earnings: 89bio Beats EPS for Q2 2024
ETNB stock results show that 89bio beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the UBS Global Healthcare Conference
From 89bio, Inc.
Via GlobeNewswire
ETNB Stock Earnings: 89bio Misses EPS for Q1 2024
ETNB stock results show that 89bio missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. 
Via Investor's Business Daily
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in Upcoming Investor Conferences
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Appoints Francis Sarena as Chief Operating Officer
From 89bio, Inc.
Via GlobeNewswire
89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment.... 
Via Benzinga
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
Researchers published results Wednesday showing Lilly's weight-loss drug could work in a liver disease. 
Via Investor's Business Daily
The Week Ahead: What's Next
The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle. 
Via Talk Markets
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
-Poster presentation selected for the EASL Poster Tour, a dedicated discussion session- 
From 89bio, Inc.
Via GlobeNewswire
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the BofA Securities 2024 Health Care Conference
From 89bio, Inc.
Via GlobeNewswire
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday, May 16th at 10am ET 
From 89bio, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.